Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.4 (trypsin)
 42,187 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chronic reserpine treatment (500 micrograms/kg) of the rat results in generalized exocrinopathy, impaired pancreatic secretion, and decreased pancreatic amylase. These characteristics are similar to those in cystic fibrosis and are the basis for use of this experimental model for cystic fibrosis. Pancreatic enzymes adapt to diet, but it is not known whether chronic reserpine treatment affects this response. Due to the malnutrition induced by this treatment, another dose of reserpine was required that would alter pancreatic function but not induce malnutrition in order to evaluate dietary adaptation. Male rats (100-120 g) were injected subcutaneously daily for 7 days with 1) no injection (control); 2) 1.0 ml/kg vehicle or sham (pair fed-sham); or 3) reserpine: 500, 50, or 5 micrograms/kg. Food consumption was comparable among control and reserpine-treated (50 and 5 micrograms/kg) rats and significantly greater (200%) than pair fed-sham and 500 micrograms/kg reserpine-treated rats. Pancreatic amylase, however, was significantly lower in all reserpine-treated rats (500 micrograms/kg, 74%; 50 micrograms/kg, 56%; 5 micrograms/kg, 52%) than in control rats. To evaluate dietary adaptation, control and reserpine-treated (5 micrograms/kg) rats were fed high carbohydrate, high fat or high protein diets. Both groups adapted to these diets with the greatest amylase, lipase, and trypsin activities in high carbohydrate-, high fat-, and high protein-fed rats, respectively. Reserpine-treated rats fed high carbohydrate, however, had significantly lower (64%) amylase activity than high carbohydrate-fed control rats. Although reserpine-treated rats can adapt pancreatic enzymes to diet, the adaptation of amylase to carbohydrate is impaired.
 ...
PMID:Effects of reserpine treatment on dietary adaptation of the rat exocrine pancreas. 245 Dec 6

Interleukin-1, first identified as a macrophage factor of importance in infections and inflammation, is a protein with properties of an endogenous pyrogene and lymphocyte activating factor. Occurrence of interleukin-1-like immunoreactivity was demonstrated in the noradrenergic chromaffin cells of the rat and mouse adrenal gland by means of two antisera raised against synthetic peptides corresponding to the amino acid sequences 169-194 and 201-215 of the murine interleukin-1 precursor protein. These antisera also inhibited stimulation of interleukin-2 receptor expression by purified human interleukin-1. Reserpine, which is known to deplete catecholamines, also caused release of the interleukin-1-like immunoreactive material. The interleukin-1 content of the rat adrenal medulla was estimated by radioimmunoassay, and if released the adrenal interleukin-1 pool may result in plasma interleukin-1 levels of about 10(-12). The interleukin-1-immunoreactive material obtained from the rat adrenal gland was characterized as a trypsin-sensitive protein with a molecular weight in the range of 13,000-19,000. This protein fraction stimulated interleukin-2 receptor expression on human T-cells as earlier shown for interleukin-1.
 ...
PMID:Interleukin-1 in adrenal chromaffin cells. 278 29

Glandular kallikrein is a major estrogen-induced protein of the rat anterior pituitary. A second kallikrein-like protease in the rat anterior pituitary (kallikrein A) is not affected by estrogens, nor is a third pituitary protease which cleaves a trypsin substrate but not kallikrein substrates. This study examined whether any of the pituitary proteases are regulated by dopaminergic mechanisms. Ovariectomized female rats were treated for 5-10 days with reserpine (a catecholamine depleting agent), haloperidol (a dopamine receptor blocker) or bromocriptine (a dopamine receptor agonist); some rats also received 1 or 2 micrograms estradiol benzoate every 48 h. Following activation of latent proteases with trypsin, anterior pituitary extracts were assayed for kallikrein activity before and after fractionation on DEAE-Sephadex to separate the two kallikrein-like proteases. Reserpine or haloperidol doubled glandular kallikrein levels in anterior pituitaries from estrogen-treated rats. Reserpine or haloperidol had little or no effect in the absence of estrogen (estrogen produced a 5- to 7-fold increase in glandular kallikrein in the absence of drug treatment). Bromocriptine markedly attenuated the ability of estrogen to induce glandular kallikrein. Further, bromocriptine blocked the ability of reserpine to increase glandular kallikrein levels, and haloperidol attenuated the effect of bromocriptine. Other anterior pituitary proteases were unaffected by either estrogen, haloperidol, reserpine or bromocriptine. The results demonstrate that the estrogen induction of glandular kallikrein in the rat anterior pituitary is modulated by inhibitory dopaminergic mechanisms. Prolactin is the only pituitary hormone which exhibits a similar profile of hormonal and neuroendocrine regulation; this suggests a possible link between glandular kallikrein and prolactin.
 ...
PMID:Dopaminergic regulation of the estrogen-induced glandular kallikrein in the rat anterior pituitary. 302 15

The intermediate lobe of the rat pituitary contains a trypsin-like protease closely related or identical to glandular kallikrein. This study examined whether glandular kallikrein in the intermediate lobe is under inhibitory control by dopaminergic systems. Male rats were treated for 4-6 days with various doses of the following drugs, alone or in combination: haloperidol (a dopamine receptor blocker), reserpine (a catecholamine depleting agent), and bromocriptine (a dopamine receptor agonist). Neurointermediate lobe (NIL) homogenates were prepared. Following activation of latent enzymes with trypsin, glandular kallikrein was measured using two chromogenic peptide substrates. Haloperidol doubled NIL glandular kallikrein activity. Dissection of the NIL revealed that haloperidol specifically increased glandular kallikrein in the intermediate lobe and had no effect on the small amount of activity in the neural lobe. Reserpine also doubled NIL glandular kallikrein and haloperidol did not produce further increases. The reserpine-induced increase in NIL glandular kallikrein was completely blocked by concurrent administration of bromocriptine: this effect was blocked by haloperidol. The results demonstrate that intermediate lobe glandular kallikrein is under inhibitory control by dopaminergic systems. This parallels the regulation of proopiomelanocortin (POMC) synthesis in the intermediate lobe and suggests that glandular kallikrein should be evaluated as a POMC-processing enzyme.
 ...
PMID:Dopaminergic regulation of glandular kallikrein in the intermediate lobe of the rat pituitary. 363 74